The medical need to treat respiratory diseases in China is unfortunately rapidly growing. Due mainly to population and industrial growth in Chinese cities, increased air pollution is becoming a major cause of human respiratory diseases. According to the Global Initiative for Asthma (GINA), there are more than 300 million asthma patients worldwide, with almost 45,7 million in China. Asthma is prevalent but largely undiagnosed (70%) and undertreated (95%) in this country (The Lancet, 2019). Chronic obstructive pulmonary disease (COPD) remains the 4th leading cause death worldwide, and is a major public health problem in China, affecting 8.2% of individuals aged ≥ 40 years.
To address the latest advances in Dry Powder Inhalation (DPI) development and formulation, in 2013, DFE Pharma organized the 1st DPI China Technology Conference. Since then, it has become a landmark event in the inhalation field. This year, the 10th DPI China is taking place in Shanghai on March 30th and 31st. Presentations will be held by renowned experts in the field of development of dry powder inhaler (DPI) products. The theme of the symposium is to focus on the new technology, market trends, regulatory, etc. of DPI development and provide the platform to network with local and global industry, It will also include a presentation regarding INTO, a unique partnership to accelerate respiratory products development.
The 10th DPI China Technology Conference
March 30 – 31, 2023
InterContinental Shanghai Jing'An (No.500 Hengfeng Rd, Shanghai, China)
Download the agenda
To request more information, please contact Eric Xie: email@example.com